FDA+ roundup: Number of drug surveillance inspections tripled from 2021 to 2022
Back in May 2020, thanks to the Covid pandemic, the FDA had to press pause on domestic and foreign routine surveillance inspections, which piled up into a backlog of nearly 8,000 inspections.
Since then, however, the agency now makes clear in a new quality report that its number of surveillance inspections tripled in the last year, from 115 inspections in 2021 to 328 surveillance inspections in 2022. Some of that progress is thanks to agreements that the agency has with other countries, as it says 129 inspection classifications were due to Mutual Recognition Agreements with foreign regulators, and 49 were surveillance systems-based assessments using information from FDA requests.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
